XBP1 and ovarian carcinoma: Additionally, targeting XBP1 specifically in tDCs through therapeutic silencing using nanoparticles or utilizing mouse models with XBP1‐deficient dendritic cells effectively controls abnormal adipogenesis while enhancing antigen presentation in the TME, thereby promoting T cell–mediated antitumor immune responses and delaying ovarian cancer progression in mouse models [100].